Completed NA INTERVENTIONAL 1-arm NCT05371899

Mass Balance Study of [14C]Chiauranib

Absorption, Metabolism and Excretion of [14C]Chiauranib in Patients With Small Cell Lung Cancer

Sponsor: Chipscreen Biosciences, Ltd.

Interventions Chiauranib

Updated 6 times since 2022 Last updated: Jul 11, 2024 Started: Jul 20, 2022 Primary completion: Mar 18, 2024 Completion: Mar 18, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Small Cell Lung Cancer and is currently completed. Chipscreen Biosciences, Ltd. leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Aug 2024 — Sep 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Recruiting NA
Sep 2023 — Jul 2024 [monthly]

Recruiting NA
Sep 2022 — Sep 2023 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jun 2022 — Sep 2022 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chipscreen Biosciences, Ltd.

Data source: Chipscreen Biosciences, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China